A Myth | GenomeWeb

A Myth

PureTech Ventures' John LaMattina this week says "there has never really been 'low-hanging fruit' in pharma R&D." Writing in Forbes, the former president of R&D at Pfizer says "the fact of the matter is that drug discovery has always been hard and that there have been spectacular failures over the years in pursuit of what its retrospectively viewed as 'low-hanging fruit,'" or easily attainable targets. "For decades, the fruit has always been hard to reach.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The White House has created a list of cuts, including to the NIH, that could be in a budget bill for this year.

The US National Institutes of Health is to allow applicants to cite preprints just as they would any other research paper, ScienceInsider reports.

Two manuscript pages handwritten by Charles Darwin are going on the auction block, according to the Los Angeles Times.

In PNAS this week: tool to track transcriptome-wide binding, evidence of balancing selection on behavior-linked genes, and more.